|
1
|
Singh S, Singh PP, Roberts LR and Sanchez
W: Chemopreventive strategies in hepatocellular carcinoma. Nat Rev
Gastroenterol Hepatol. 11:45–54. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ming Y, Zheng Z, Chen L, Zheng G, Liu S,
Yu Y and Tong Q: Corilagin inhibits hepatocellular carcinoma cell
proliferation by inducing G2/M phase arrest. Cell Biol Int.
37:1046–1054. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jia L, Jin H, Zhou J, Chen L, Lu Y, Ming Y
and Yu Y: A potential anti-tumor herbal medicine, Corilagin,
inhibits ovarian cancer cell growth through blocking the TGF-β
signaling pathways. BMC Complement Altern Med. 13:332013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmidt OT and Lademann R: Corilagin, ein
weiterer kristallisierter Gerbstoff aus Dividivi. X. Mitteilung
über natürliche Gerbstoffe. Justus Liebigs Ann Chem. 571:232–237.
1951.(In German). View Article : Google Scholar
|
|
5
|
Pham AT, Malterud KE, Paulsen BS, Diallo D
and Wangensteen H: DPPH radical scavenging and xanthine oxidase
inhibitory activity of Terminalia macroptera leaves. Nat
Prod Commun. 6:1125–1128. 2011.PubMed/NCBI
|
|
6
|
Yang F, Wang Y, Xue J, Ma Q, Zhang J, Chen
YF, Shang ZZ, Li QQ, Zhang SL and Zhao L: Effect of Corilagin on
the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced
hepatic fibrosis mouse model. Parasitol Int. 65:308–315. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dong XR, Luo M, Fan L, Zhang T, Liu L,
Dong JH and Wu G: Corilagin inhibits the double strand
break-triggered NF-kappaB pathway in irradiated microglial cells.
Int J Mol Med. 25:531–536. 2010.PubMed/NCBI
|
|
8
|
Park JH, Joo HS, Yoo KY, Shin BN, Kim IH,
Lee CH, Choi JH, Byun K, Lee B, Lim SS, et al: Extract from
Terminalia chebula seeds protect against experimental
ischemic neuronal damage via maintaining SODs and BDNF levels.
Neurochem Res. 36:2043–2050. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Duan W, Yu Y and Zhang L: Antiatherogenic
effects of phyllanthus emblica associated with corilagin and its
analogue. Yakugaku Zasshi. 125:587–591. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang MH, Vasquez Y, Ali Z, Khan IA and
Khan SI: Constituents from Terminalia species increase PPARα
and PPARγ levels and stimulate glucose uptake without enhancing
adipocyte differentiation. J Ethnopharmacol. 149:490–498. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gambari R, Hau DK, Wong WY and Chui CH:
Sensitization of Hep3B hepatoma cells to cisplatin and doxorubicin
by corilagin. Phytother Res. 28:781–783. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang BQ: Corilagin nanoparticle-induced
apoptosis in human gastric cancer SGC-7901 cells via the
mitochondrial pathway. Acta Pharmacol Sin. 34:14. 2013.
|
|
13
|
Kakiuchi N, Hattori M, Namba T, Nishizawa
M, Yamagishi T and Okuda T: Inhibitory effect of tannins on reverse
transcriptase from RNA tumor virus. J Nat Prod. 48:614–621. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berry DE, MacKenzie L, Shultis EA, Chan JA
and Hecht SM: Naturally occurring inhibitors of topoisomerase I
mediated DNA relaxation. J Org Chem. 57:420–422. 1992. View Article : Google Scholar
|
|
15
|
Hecht SM, Berry DE, MacKenzie LJ, Busby RW
and Nasuti CA: A strategy for identifying novel, mechanistically
unique inhibitors of topoisomerase I. J Nat Prod. 55:401–413. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Komori A, Yatsunami J, Suganuma M, Okabe
S, Abe S, Sakai A, Sasaki K and Fujiki H: Tumor necrosis factor
acts as a tumor promoter in BALB/3T3 cell transformation. Cancer
Res. 53:1982–1985. 1993.PubMed/NCBI
|
|
17
|
Okabe S, Suganuma M, Imayoshi Y, Taniguchi
S, Yoshida T and Fujiki H: New TNF-alpha releasing inhibitors,
geraniin and corilagin, in leaves of Acer nikoense,
Megusurino-ki. Biol Pharm Bull. 24:1145–1148. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang YJ, Nagao T, Tanaka T, Yang CR,
Okabe H and Kouno I: Antiproliferative activity of the main
constituents from Phyllanthus emblica. Biol Pharm Bull.
27:251–255. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Z, Wang D, Chen Y, Ren L, Li K and
Zhang W: Experiment studies on the pharmacodynamics experiment by
corilagin. Zhongliu Fangzhi Yanjiu. 29:356–358. 2002.
|
|
20
|
Chen Y and Ren L: Studies on the
anti-cancer active constituents of matsumura leafflower
(Phyllanthus matsumarae) II. Isolation and identification of
polyphenolic compounds. Chin Tradit Herbal Drugs. 28:198–202.
1997.
|
|
21
|
Zheng ZZ, Chen LH, Liu SS, Deng Y, Zheng
GH, Gu Y and Ming YL: Bioguided fraction and isolation of the
antitumor components from Phyllanthus niruri L. Biomed Res
Int. 2016:97292752016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jia L, Zhou J, Zhao H, Jin H, Lv M, Zhao
N, Zheng Z, Lu Y, Ming Y and Yu Y: Corilagin sensitizes epithelial
ovarian cancer to chemotherapy by inhibiting Snail glycolysis
pathways. Oncol Rep. 38:2464–2470. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chazotte B: Labeling mitochondria with
JC-1. Cold Spring Harb Protoc. Sep 1–2011.(Epub ahead of print).
doi: 10.1101/pdb.prot065490. View Article : Google Scholar
|
|
24
|
Lampson BL and Davids MS: The development
and current use of BCL-2 inhibitors for the treatment of chronic
lymphocytic leukemia. Curr Hematol Malig Rep. 12:11–19. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shamsabadi FT, Eidgahi MR, Mehrbod P,
Daneshvar N, Allaudin ZN, Yamchi A and Shahbazi M: Survivin, a
promising gene for targeted cancer treatment. Asian Pac J Cancer
Prev. 17:3711–3719. 2016.PubMed/NCBI
|
|
26
|
Coutts AS, Adams CJ and La Thangue NB: p53
ubiquitination by Mdm2: A never ending tail? DNA Repair (Amst).
8:483–490. 2009. View Article : Google Scholar : PubMed/NCBI
|
